Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
|Articles|March 24, 2023
5 Key Sessions, Interviews at 2023 APhA Annual Meeting & Exposition
Author(s)Erin Hunter, Assistant Editor
Pharmacy Times is covering the American Pharmacists Association (APhA) Annual Meeting & Exposition in Phoenix, Arizona from March 24 to 27, 2023.
Advertisement
The theme of this year’s APhA meeting is “Rise! Advancing in the Face of Adversity.” The gathering will provide pharmacy professionals with the opportunity to learn about innovations in the industry, connect with other pharmacists, and work together to tackle obstacles with ingenuity and creativity.
Stay tuned on PharmacyTimes.com for exclusive session coverage and interviews with experts, including:
- Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, dean and professor at Loma Linda University School of Pharmacy, who will provide an update on the 2023 immunization recommendations and offer insight about the status of COVID-19 vaccines.
- Coverage of a session on pain management that delves into alternative, non-pharmacologic interventions to treat chronic pain and develop appropriate treatment strategies.
- A discussion with Kathryn Marwitz, PharmD, MPH, who will dive into debunking misinformation in the pharmacist’s workplace. She will explore social media, the repercussions of patient wellbeing because of misinformation, and how to help facilitate communication of truthful scientific information.
- Coverage of a session on adult ADHD which will delve into how ADHD affects adult patients, and how pharmacists can create a plan to help patients manage the condition.
- A conversation with Vibhuti Arya, PharmD, MPH, FAPhA, who will discuss drug decriminalization, it’s impact on public health, and how pharmacy professionals can address its stigma with patients.
Stay tuned on
Advertisement
Related to this article
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Novo Nordisk's top-line phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5